Skip to main content
. 2020 May 13;25(8):702–711. doi: 10.1634/theoncologist.2020-0088

Figure 2.

Figure 2

PD‐L1 expression in ALK‐positive adenocarcinoma (ADC). (A): Compared with EGFR/ALK WT tumors, PD‐L1 expression was lower in ALK‐positive lung ADC (p = .009), whereas EGFR‐mutant ADC exhibited significantly lower PD‐L1 expression (p < .001). (B): The difference in PD‐L1 expression between ALK tumors with short variants and long variants. Tumors with short variants (V3 and V5) tended to have higher PD‐L1 expression (p = .03). (C): The association of PD‐L1 and metastatic sites in patients with ALK‐positive ADC. Tumors with PD‐L1 ≥50% were more likely to have liver metastases.

Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; PD‐L1, programmed death‐ligand 1; TPS, tumor proportion score; V, variant; WT, wild type.